Kent Hawryluk, MBX Biosciences CEO
September 9, 2024 07:35 AM EDT
Financing
Startups

MBX seeks $114M IPO to com­pete with As­cendis and get a long-act­ing GLP-1/GIP pro­drug in­to the clin­ic

Kyle LaHucik

Senior Reporter

MBX Bio­sciences is the lat­est IPO con­tender af­ter sub­mit­ting its pitch for a $114 mil­lion Nas­daq de­but, which will go to­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Arv­inas touts healthy vol­un­teer da­ta for Parkin­son's dis­ease PRO­TAC

No­vo Nordisk ad­justs its lead­er­ship team; Dyne alums mi­grate to Cres­cent Bio­phar­ma

FDA will con­sol­i­date to five 'shared ser­vices of­fices,' ac­cord­ing to memo to Hill staffers

Eli Lil­ly pays strug­gling Sang­amo $18M up­front to tap gene ther­a­py cap­sid

F-star man­age­ment takes com­pa­ny pri­vate, two years af­ter $161M cash ex­it to Sino's in­voX

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times